Abstract

To assess the effectiveness of Xingnaojing injection in conjunction with Ginkgo biloba extract in managing post-stroke cognitive impairment. The period from June 2022 to June 2023 saw the treatment of 100 patients with post-stroke cognitive impairment at our hospital, all of whom were included in this study. The patients were then randomly assigned to an observation group (n=50) and a control group (n=50). While the control group was provided with intravenous infusion of Xingnaojing injection, the observation group, following the control group’s protocol, underwent treatment involving a combination of Xingnaojing injection and Ginkgo biloba extract injection. Both groups underwent therapy for a continuous 14 d period. During the treatment, the evaluation criteria encompassed the effectiveness of treatment, neural function (brain-derived neurotrophic factor, nerve growth factor), cognitive function (National Institute of Health Stroke Scale, activities of daily living, mini-mental state examination), neurotransmitter levels, and any unfavorable responses to the drugs. A notable distinction was observed, with the overall effective rate being significantly higher in the observation group (94.23 %) than in the control group (77.08 %). The incidence of adverse drug reactions showed no notable difference between the control and observation groups. Significant clinical effectiveness is evident in the treatment of poststroke cognitive impairment with the utilization of Xingnaojing injection in conjunction with Ginkgo biloba extract. It effectively enhances neural and cognitive function while ensuring safety for patients. The potential exists for this treatment approach to emerge as a key strategy in stroke rehabilitation and offer valuable insights for clinical treatment decisions. Nevertheless, additional extensive and prolonged follow-up studies are necessary to verify and reinforce these outcomes.